T A B L E O F C O N T E N T S

Main results
We found 38 trials meeting the inclusion criteria and reporting death as an outcome. There were 1,958 deaths among 10,842 trial participants.
For hypovolaemia, the relative risk of death following albumin administration was 1.02 (95% confidence interval (CI) 0.92 to 1.13). This estimate was heavily influenced by the results of the SAFE trial, which contributed 75.2% of the information (based on the weights in the meta-analysis). For burns, the relative risk was 2.93 (95% CI 1.28 to 6.72) and for hypoalbuminaemia the relative risk was 1.26 (95% CI 0.84 to 1.88). There was no substantial heterogeneity between the trials in the various categories (Chi 2 = 26.66, df = 31, P = 0.69). The pooled relative risk of death with albumin administration was 1.05 (95% CI 0.95 to 1.16).
Authors' conclusions
For patients with hypovolaemia, there is no evidence that albumin reduces mortality when compared with cheaper alternatives such as saline. There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminaemia. The possibility that there may be highly selected populations of critically ill patients in which albumin may be indicated remains open to question. However, in view of the absence of evidence of a mortality benefit from albumin and the increased cost of albumin compared to alternatives such as saline, it would seem reasonable that albumin should only be used within the context of well concealed and adequately powered randomised controlled trials.
P L A I N L A N G U A G E S U M M A R Y
What is the effect of giving human albumin compared to saline to replace lost blood in critically ill or injured people Trauma, burns or surgery can cause people to lose large amounts of blood. Fluid replacement, giving fluids intravenously (into a vein), is used to help restore blood volume and hopefully reduce the risk of dying. Blood products (including human albumin), non-blood products or combinations can be used. This review of 38 trials found no evidence that albumin reduces the risk of dying. Albumin is very expensive, in which case it may be better to use cheaper alternatives such as saline for fluid replacement.
B A C K G R O U N D
In patients with acute and chronic illness, serum albumin concentration is inversely related to mortality risk. A systematic review of cohort studies meeting specified criteria estimated that, for each 2.5 g/L decrement in serum albumin concentration, the risk of death increases by between 24% and 56% (Goldwasser 1997) . The association persists after adjusting for other known risk factors and pre-existing illness, suggesting a direct protective effect of the albumin molecule (Goldwasser 1997) . Largely as a result of these observations, human albumin solutions are now used in the management of a diverse range of medical and surgical problems. Published indications for human albumin solution include the emergency treatment of shock and other conditions where restoration of blood volume is urgent, the acute management of burns, and clinical situations associated with hypoproteinaemia (ABPI 1998).
In comparison with other colloidal solutions and with crystalloid solutions, human albumin solutions are expensive (McClelland 1990) . Volume for volume human albumin solution is twice as expensive as hydroxyethyl starch, and over 30 times more expensive than crystalloid solutions such as sodium chloride or Ringer's lactate. Because of the high cost and limited availability of human albumin, it is particularly important that its use should be restricted to the indications for which it has been shown to be effective. To assess the effectiveness and safety of human albumin solutions in the management of critically ill patients, particularly those with hypovolaemia from injury or surgery, burns and hypoproteinaemia, a systematic review of randomised controlled trials was conducted.
O B J E C T I V E S
To quantify the effect on mortality of human albumin administration in the management of critically ill patients.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We sought to identify all randomised controlled trials of human albumin or plasma protein fraction (PPF) administration (albumin or PPF versus no albumin or PPF, or a crystalloid solution).
Types of participants
Critically ill patients with hypovolaemia, burns or hypoproteinaemia. Trials involving patients receiving pre-operative volume loading or haemodilution, and trials of albumin administration during paracentesis, were excluded.
Types of interventions
Human albumin solution or plasma protein fraction (PPF).
Types of outcome measures
The principal outcome measure was mortality from all causes assessed at the end of the follow-up period scheduled for each trial.
Search methods for identification of studies
The latest search was carried out in May to June 2011 using the electronic databases listed below. See Figure 1 for the study identification and selection process for this update.
Figure 1. PRISMA diagram: study identification and selection process-latest update only
Search strategies used for previous versions of this review can be obtained from the Trials Search Co-ordinator of the Cochrane Injuries Group.
Electronic searches
We searched the following electronic databases:
• Cochrane Injuries Group Specialised Register (searched May 31 2011);
• Cochrane Central Register of Controlled Trials (The Cochrane Library 2011, Issue 2);
• MEDLINE(Ovid) (1948 to week 3 May 2011);
• Embase (Ovid) (1980 to Week 21 2011);
• CINAHL (EBSCO) (1982 to May 2011);
• ISI Web of Science: Science Citation Index Expanded (SCI-EXPANDED) (1970 to May 2011);
• ISI Web of Science: Conference Proceedings Citation Index -Science (CPCI-S) (1990 to May 2011);
• PubMed (www.ncbi.nlm.nih.gov/sites/entrez/) (searched 10 June 2011, limit: last 60 days).
Full details of the latest search strategies can be found in Appendix 1.
Searching other resources
For the original searches, trials were identified using BIDS Index to Scientific and Technical Proceedings and by handsearching 29 international journals and the proceedings of several international meetings on fluid resuscitation. To identify unpublished trials we searched the register of the Medical Editors' Trial Amnesty, and contacted the Medical Directors of Bio Products Laboratory (Zenalb), Centeon Limited (Albuminar), and Alpha Therapeutic UK Limited (Albutein). We have subsequently identified studies by examining reference lists of included studies and previously published reviews. We have also contacted authors of included studies to enquire about other published or unpublished studies that they may be aware of. We did not limit our searches by date, language or publication status.
Data collection and analysis
One author scanned the titles and abstracts of reports identified by electronic searching to produce a list of possibly relevant reports. Two authors (PA and IR) then checked the list to determine which articles to retrieve in full. Disagreements were resolved by discussion. The same two authors applied the selection criteria, again resolving disagreements by discussion. They both extracted data on study design, allocation concealment, participants, interventions and mortality. One author (IR) entered the data into Review Manager and the other (PA) checked it against his data extraction.
Where clarification on any aspect of a study was needed, one review author contacted the author of the trial. Relative risks and 95% confidence intervals (CI) for mortality were calculated for each trial on an intention-to-treat basis. Heterogeneity between trials was tested using a Chi 2 test, where P ≤ 0.05 was taken to indicate significant heterogeneity. As long as statistical heterogeneity did not exist, for dichotomous data summary relative risks and 95% CIs were calculated using a fixed-effect model. In the event of statistical heterogeneity, if the source of heterogeneity could obviously be related to patient type, or allocation concealment, we stratified the analyses on that dimension.
R E S U L T S
Description of studies
See: Characteristics of included studies; Characteristics of excluded studies. A total of 38 randomised controlled trials were identified that met the study inclusion criteria. Mortality data were available either from the published report or on contact with the authors of 38 of these trials. The five trials for which mortality data could not be obtained (Ernest 1999; Ernest 2001; McNulty 1993; Oca 1999; Skillman 1975) included a total of 124 randomised patients, comprising 1.14% of the total number of randomised patients in all trials meeting the study inclusion criteria. One of the trials was an unpublished trial registered in the Medical Editors' Trial Amnesty (Woittiez 1998) . Further details about this trial, including data on mortality, were obtained directly from the trialist. In six trials there were no deaths in either the intervention or comparison groups. An intention-to-treat analysis could not be done for nine of 50 patients in one study (Oca 2003) consequently mortality data is only presented for 41 patients. The trial by Lucas et al was reported in five publications. An early report gave the mortality data for 52 randomised patients, 27 allocated to receive albumin, 25 allocated to receive no albumin (Lucas 1978) . Subsequent publications indicated that recruitment to the trial continued until 94 patients were randomised. Mortality data for all the 94 patients were not published, nor were they available on contact with the author. Consequently the outcome data for the 52 patients are presented. For the 32 included trials in which there were one or more deaths in either the intervention or control groups, allocation concealment involved a method that would be expected to reduce the risk of foreknowledge of treatment allocation (pharmacy controlled randomisation or serially numbered sealed opaque envelopes) in 20 trials, was unclear in eight trials, and inadequate in four trials. Bland 1973 Randomised control trial. Therapy cards were randomised in pairs matched for weight. Method of allocation concealment was not described. Bland 1976 This study is reported as randomised but the method of allocating random numbers and method of allocation concealment are unknown. Boldt 1993 Randomised controlled trial. Allocation concealment was by the use of sealed opaque envelopes.
Risk of bias in included studies
Boutros 1979
The study is reported as randomised but the method of randomisation and allocation concealment are unknown.
Brown 1988
The random sequence was generated using random number tables. No allocation concealment.
Cooper 2006
Randomisation was accomplished with a computer-generated list and sequentially numbered sealed, opaque envelopes. Dubois 2006 Eligible patients were randomised in a 1:1 ratio using sealed envelopes. Ernest 1999 Randomisation was done by the hospital chart number (odd or even).
Ernest 2001
Randomisation was done by the hospital record number (odd or even).
Foley 1990
Patients were randomly assigned to either a treatment or nontreatment group by medical record number. Gallagher 1985 Randomisation and allocation concealment were by computerised system. Golub 1994 Random sequence was computer generated. Allocation concealment was by the use of sealed opaque envelopes. Goodwin 1983 Randomisation was according to random number tables. The methods of allocation concealment were unknown. Greenhalgh 1995 Randomisation scheme controlled by the pharmacy. Greenough 1993 Randomised controlled trial. Allocation concealment was by the use of sealed opaque envelopes.
Grundmann 1982
The study is reported as prospectively randomised, but the methods of randomisation and allocation concealment are unknown.
Jelenko 1978
The study is reported as randomised but the method of randomi-sation and allocation concealment are unknown.
Kanarek 1992 Randomised controlled trial. Allocation concealment was by the use of sealed opaque envelopes. Lowe 1977 The method of allocating random numbers is unknown. Sealed envelopes were used to ensure allocation concealment.
Lucas 1978
Allocation was based on the last digit of each patient's case number. Ninety-four patients were randomised in total but the number of deaths was not reported in the final report. However, in a preliminary report, based on 52 of the randomised patients, deaths were reported.
Maitland 2005
Randomised control trial using a sealed card system.
Maitland 2011
Multicentre, open, randomised, controlled study. Sealed opaque envelopes were used to assist allocation concealment.
McNulty 1993
The study is reported as randomised but the method of randomisation and allocation concealment are unknown. Nielsen 1985 This study is reported as randomised but the method of allocation concealment is not described. Nilsson 1980 Randomised controlled trial. Allocation concealment was by the use of sealed opaque envelopes. Oca 1999 Randomisation was done by sequentially numbered, sealed, opaque envelopes. Oca 2003 Randomisation was accomplished by random number tables via sealed, serially numbered envelopes.
Pockaj 1994
Prien 1990
The study is reported as randomised but the method of randomisation and allocation concealment are unknown. Quinlan 2004 Randomised double blind controlled trial. Rackow 1983 Randomisation was according to a pre-determined randomisation schedule, but the methods and the allocation concealment are unknown. Rubin 1997 Allocation concealment was by a sealed opaque envelope system in the hospital pharmacy.
SAFE 2004
Central randomisation accessed on the Internet through a secure website with use of a minimisation algorithm. Blinding was assured through the use of specially designed masking cartons and specially designed and manufactured administration sets. The authors report that the effectiveness of the blinding was confirmed in a formal study before the trial was initiated. Shah 1977 Randomised controlled trial. Allocation by sealed envelope.
Skillman 1975
The study is reported as randomised but the method of randomisation and allocation concealment are unknown. So 1997 Randomised controlled trial. Allocation concealment was by computerised system. Tollofsrud 1995 The method of generating random numbers is unknown. Allocation concealment was by sealed opaque envelopes. Virgilio 1979 Randomisation was determined using random number tables. Methods of allocation concealment are unknown. Woittiez 1998 Randomised controlled trial. Allocation concealment was by the use of sealed opaque envelopes. Wojtysiak 1992 Randomisation was determined using random number tables. Allocation concealment was inadequate. Woods 1993 Patients with even hospital numbers were allocated to the group receiving albumin, while those with odd hospital numbers were allocated to the group not receiving supplemental albumin.
Zetterstrom 1981a
Patients were randomly divided into two groups. Allocation concealment was by the use of sealed opaque envelopes.
Zetterstrom 1981b
Effects of interventions
For hypovolaemia the pooled relative risk of death following albumin administration was 1.02 (95% confidence interval (CI) 0.92 to 1.13). This estimate was heavily influenced by the results of the SAFE trial which received 75.2% of the weight. For burns the relative risk was 2.93 (95% CI 1.28 to 6.72), and for hypoalbuminaemia the relative risk was 1.26 (95% CI 0.84 to 1.88). There was no substantial heterogeneity between the trials in the various categories (Chi 2 = 26.66, df = 31, P = 0.69). The pooled relative risk of death with albumin administration was 1.05 (95% CI 0.95 to 1.16).
D I S C U S S I O N
Because many of the trials included in this meta-analysis are small and many are poorly concealed, the results must be interpreted with caution. The SAFE trial, however, is a notable exception. The SAFE trial included a total of 6997 randomised participants, allocation was well concealed, the use of a minimisation algorithm helped to ensure that baseline characteristics were well balanced, vigorous attempts were made to ensure that the participating clinicians were blind to the type of fluid that was administered, and an intention-to-treat analysis was undertaken. The SAFE trial provided no evidence that albumin reduced mortality in patients with hypovolaemia, although the possibility of a modest benefit or harm could not be excluded.
This systematic review was first updated in November 2001. At that time, one additional trial was identified and included (Bland 1973) . This trial compared albumin and dextrose infusions in new-born infants with low cord serum protein levels who were considered to be at risk of respiratory distress. This trial meets the eligibility criteria for the review (hypoproteinaemia) but had been overlooked in the original search. However, the inclusion of this trial does not change the conclusions of the review. The latest update of this review (July 2011) includes one further recently published trial that meets the inclusion criteria (Maitland 2011); it does not change the conclusions of the review.
Summary of main results
There is no evidence that albumin reduces mortality in patients with hypovolaemia, burns or hypoproteinaemia. For patients with burns or hypoproteinaemia, there is a suggestion that albumin administration may increase mortality. Mortality was selected as the outcome measure in this systematic review for several reasons. In the context of critical illness, death or survival is a clinically relevant outcome that is of immediate importance to patients, and data on death are reported in nearly all studies. Furthermore, one might expect that mortality data would be less prone to measurement error or biased reporting than would data on pathophysiological outcomes. The use of a pathophysiological end-point as a surrogate for an adverse outcome assumes a direct relationship between the two, an assumption that may sometimes be inappropriate. Finally, when trials collect data on a number of physiological end-points, there is the potential for bias due to the selective publication of end-points showing striking treatment effects. Because we obtained mortality data for all but four of the included trials, the likelihood of bias due to selective publication of trial outcomes is minimal.
Potential biases in the review process
Although publication bias is a potent threat to the validity of systematic reviews, it is unlikely to have had an important impact in this study. There was no evidence of funnel plot asymmetry on visual inspection. In some of the trials included in this review, allocation concealment was inadequate or was unclear. As a result, it is possible that more severely ill patients were preferentially allocated to the albumin treated group, which may account for the increased mortality risk in this group. Nevertheless, when the analyses were repeated, including only those trials in which allocation concealment involved a method that would be expected to reduce the risk of foreknowledge of treatment allocation, the point estimates were little different.
A U T H O R S ' C O N C L U S I O N S
Implications for practice
For patients with hypovolaemia there is no evidence that albumin reduces mortality when compared with cheaper alternatives such as saline. There is no evidence that albumin reduces mortality in critically ill patients with burns and hypoalbuminaemia and there is a suggestion that albumin may increase the risk of death.
Implications for research
The possibility that there may be highly selected populations of critically ill patients in which albumin may be indicated remains open to question. However, in view of the absence of evidence of a mortality benefit from albumin and the increased cost of albumin compared to alternatives such as saline, it would seem reasonable that albumin should only be used within the context of well concealed and adequately powered randomised controlled trials.
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R E F E R E N C E S
References to studies included in this review
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Bland 1973
Methods
Randomised controlled trial. Therapy cards were randomised in pairs matched for weight. Method of allocation concealment not fully described
Participants
Newborn infants considered at high risk for developing respiratory distress. Those with a cord serum protein level less than 4.6g/100ml and at least one of the following; birthweight less than 2500g, gestational age less than 37 weeks, arterial pH less than 7.25
Interventions 1) Intervention (n=50) received 8ml/kg 25% salt poor albumin.
2) Control group (n=50) received 8ml/kg 5% dextrose in water
Outcomes
Deaths reported within 28 days.
Notes
Bland 1976
Methods Randomised controlled trial. Method of allocation concealment not fully described
Participants
Premature infants (less than 37 weeks gestation), with hypoproteinaemia (cord serum total protein of 4.6g/100ml or less)
Interventions 1) Intervention group (n=14) received 8ml/kg salt-poor albumin.
2) Comparison group (n=13) received 8ml/kg glucose in water.
Outcomes
Deaths reported.
Notes
Length of follow-up unspecified.
Boldt 1993
Methods Randomised controlled trial. Method of allocation concealment not described in published report. Authors were contacted and confirmed the use of sealed opaque envelopes
Participants
Men undergoing elective aortocoronary bypass grafting, who had a pulmonary capillary wedge pressure of less than 5mmHg after induction of anaesthesia 
Notes
Follow-up to 48 hours after the end of the operation.
Brown 1988
Methods Randomised controlled trial. Patients entered into the study were assigned to one of two treatment groups by a table of random numbers. Method of allocation concealment not described. Author contacted -no allocation concealment Participants All patients who required central TPN and had hypoalbuminaemia (serum albumin concentration below 3.0g/dl). Patients who were thermally injured, had nephrotic syndrome or required protein restriction were excluded Interventions 1) The intervention group received central TPN plus normal serum albumin (n=33).
2) The control group (n=34) received central TPN alone.
Outcomes
Notes
Follow-up to discharge.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment (selection bias) High risk
Cooper 2006
Methods Randomised controlled trial, not blinded.
Participants
Eligible adults over 15 years old suffering from thermal injury not more than 12 hours before enrolment Interventions 1) Intervention (n=19) received 5% albumin plus Ringer's lactate.
2) Control (n=23) received Ringer's lactate.
Outcomes
Multiple Organ Dysfunction Score (MODS) and deaths reported.
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment (selection bias) Low risk "Patients were allocated to study groups with stratified randomization with a computergenerated randomization list and sequentially numbered sealed, opaque envelopes. Randomization was stratified by center..." p. 81
Dubois 2006
Methods Prospective, controlled, randomized, open, single centre study
Participants
All patients admitted to the hospital ICU with serum albumin less than or equal to 30g/ L/. Exclusion criteria were expected length of stay <72 hrs., life expectancy <3 months or a do not resuscitate order, albumin administration in the preceding 24 hrs. or evidence of fluid overload Interventions 1) Intervention (n=50) received 300 mL of 20% albumin solution on day 1 and 200 mL on subsequent days when serum albumin concentration was lower than 31 g/L.
2) Control (n=50) received Ringer's Lactate.
Outcomes
Effect of albumin on organ function as assessed by a delta Sequential Organ Failure Assessment score. Deaths not reported
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment (selection bias) Low risk "Eligible patients were randomized in a 1: 1 ratio using sealed envelopes. When a patient was assigned to one group, he or she remained in that group whether or not he or
Dubois 2006 (Continued)
she received the planned treatment."
Ernest 1999
Participants 18 septic, critically ill patients where a fluid infusion was clinically indicated
Interventions 1) 5% albumin (n=9).
2) normal saline (n=9).
Outcomes
Information on death not collected.
Notes
Follow up for about an hour after infusion.
Risk of bias
Bias Authors' judgement Support for judgement
Ernest 2001
Participants 40 postoperative cardiac surgical patients.
Interventions 1) 5% albumin (n=23).
2) normal saline (n=17).
Outcomes
Notes
Follow up for 40 minutes after infusion. Trial conducted in 1992 
Risk of bias
Foley 1990
Methods
Patients were randomly assigned to either a treatment or non-treatment group by medical record number Participants Hypoalbuminaemic (serum albumin <25g/L) critically ill patients. Potential subjects with Child's class C cirrhosis were excluded Interventions 1) The treatment group (n=18) received 25-50g per day of 25% albumin in addition to full nutritional support with parenteral nutrition. Albumin administration was continued daily until serum albumin levels exceeded 25 g/L after which patients received additional albumin as needed to keep the albumin level at 25 g/L or higher.
2) The non treatment group (n=22) received no exogenous concentrated albumin Outcomes Deaths reported.
Notes
Follow up to discharge.
Risk of bias
Bias Authors' judgement Support for judgement
Gallagher 1985
Methods Randomised controlled trial. Method of allocation concealment not described. Author contacted -allocation concealment by computerised system -patient details were entered before treatment assignment was revealed Participants Patients after coronary artery bypass graft surgery.
Interventions 1) Treatment group received 5% albumin (n=5).
2) The control group received lactated Ringers (n=5).
Outcomes
Deaths were not reported. Author contacted and confirmed that there were no deaths in either group
Notes
Follow-up to 1 day.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment (selection bias) Low risk
Golub 1994
Methods
Computer randomisation -method of allocation concealment not described. Author contacted and confirmed that allocation concealment was by the use of sealed opaque envelopes
Participants
Patients in the surgical intensive care unit of a community hospital with circulating albumin concentrations of <3.0g/dL Interventions 1) The treatment group (n=116) received 37.5g/day of albumin until the circulating albumin concentration increased to 3.0g/dL.
2) The control group received no supplemental albumin. Both groups received standard nutritional support.
Outcomes
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment (selection bias) Low risk
Goodwin 1983
Methods Randomised controlled trial. Method of allocation concealment not described Participants 79 thermally injured patients. No other inclusion criteria were reported. All of the participants were previously healthy young adults
Interventions 1) The treatment group (n=40) group received 2.5% albumin in Ringer's lactate.
2) The control group (n=39) Ringers lactate. Allocated fluid was used throughout resuscitation Outcomes Deaths reported.
Notes
Greenhalgh 1995
Methods
Method of random allocation not described. Author contacted and confirmed the use of a randomisation scheme controlled by the pharmacy Participants Patients aged 18 years or younger with acute burns.
Interventions 1) High albumin group (n=34): Patients were supplemented with human albumin to maintain serum levels between 2.5 and 3.5g/dL. Albumin was supplied as a continuous drip of 25% human albumin at a rate of 3-10mL/hour. Supplementation was discontinued if serum albumin levels remained >2.5 g/dL without supplementation or if intravenous support was discontinued.
Greenhalgh 1995 (Continued)
2) Low albumin group (n=36): Patients were not given albumin supplementation unless levels dropped <1.5 g/dL. During burn shock, patients were allowed to receive albumin if they had levels <2.0 g/dL and were receiving >4 mL/Kg/% burn fluid resuscitation Outcomes Deaths reported.
Notes
Follow-up to discharge. 
Risk of bias
Notes
In the final report of 94 randomised patients deaths were not reported. However, in this preliminary report of 52 injured patients deaths were reported
Risk of bias
Bias Authors' judgement Support for judgement
Maitland 2005
Methods Unblinded, randomised, controlled trial.
Participants
Kenyan children older than 2 months with symptomatic sever malarial anaemia (haemoglobin less than 5g/dl) Interventions 1) Intervention (n=23) received 4.5% albumin.
2) Intervention (n=20) received 0.9% saline.
3) Control (n=18) received only maintenance (rescue emergency intervention when required)
Maitland 2005 (Continued)
Outcomes Change in perfusion rates. Deaths not reported.
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment (selection bias) Low risk "On admission to the HDU, children were randomly assigned to PTM with one of the three treatments using sealed card system. The sealed cards were available 24h/day; either the admitting doctor or nurse assigned the therapy at admission based on laboratory results or, in an emergency, on clinical suspicion." p. 128
Maitland 2011
Methods Multicentre open, randomised, controlled study Participants Children (n=3170) aged between 60 days and twelve years of age, with severe febrile illness, randomly assigned within two strata (stratum A was children with severe febrile illness and impaired perfusion but without severe hypotension -stratum B was children with severe hypotension)
Interventions
Children were randomly allocated to rapid volume replacement over the course of 1 hour with either: 1) 20 ml 5% Human Albumin solution per kg body weight (n=1063) 2) 20 ml 0.9% Saline solution per kg body weight (n=1063)
Outcomes
Mortality at 4 weeks after randomisation Notes Children (n=1044) assigned to no treatment were not included in the analysis 
Risk of bias
McNulty 1993
Methods
Randomised controlled trial. Method of allocation concealment not described Participants 28 Patients following elective cardiopulmonary bypass.
Interventions 1) Intervention group (n=14) received 5% albumin.
2) Control group (n=14) received isotonic crystalloid.
Outcomes
Deaths not reported.
Notes
Myburgh 2007
Methods A double blind, randomised, controlled SAFE 2004 trial. "Randomization was stratified by a diagnosis of trauma (defined as injury to the body caused by mechanical forces, excluding burns)." p. 875
Participants 460 patients with traumatic brain injuries.
Interventions 1) Intervention (n=231) received 4% albumin.
2) Control (n=229) received normal saline.
Outcomes
Mortality rate at 28 days. 
Notes
Risk of bias
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Oca 1999
Methods Randomised controlled trial. Allocation concealment was by the use of sealed opaque sequentially numbered envelopes. Information obtained on contact with the author Participants 24 neonates being treated for hypotension. Hypotension was defined as an oscilometric mean arterial blood pressure <30 mmHg for at least 30 minutes. Exclusion criteria consisted of proven sepsis, life-threatening congenital abnormalities, congenital hear disease, unresolved thoracic air leak, insulin-requiring maternal diabetes mellitus or treatment with high-frequency ventilation Interventions 1) 5% albumin (n=11).
2) normal saline (n=13).
Outcomes
Mean arterial blood pressure.
Notes
Risk of bias
Oca 2003
Methods
Randomised, unblinded, controlled trial.
Participants
Newborn infants who were <24 hours old and were admitted to the ICU to receive one of two solutions for volume expansion. 41 infants were included in the trial Interventions 1) Intervention (n=21) received 4% albumin.
2) Control (n=20) received normal saline.
Outcomes
Magnitude of change in mean arterial blood pressure.
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment (selection bias) Low risk "Randomization was accomplished by random number tables via sealed, serially numbered envelopes" p. 474
Pockaj 1994
Methods Randomised controlled trial. Method of allocation concealment not described Participants Participants required fluid resuscitation as a result of vascular leak syndrome associated with Interleukin-2 therapy for metastatic cancer Interventions 1) Intervention group (n=54) received 5% albumin n 154meq/L NaCl; 2) Control group (n=53) received 0.9% normal saline with 154Meq/L NaCl Outcomes Deaths reported.
Notes
Prien 1990
Methods Randomised controlled trial. Method of allocation concealment not described
Participants Patients undergoing hemipancreato-duodenectomy (Whipple's operation)
Interventions 1) Intervention group (n=6) received 20% human albumin to maintain central venous pressure at the pre-operative level.
2) Control group (n=6) received Ringer's lactate.
Outcomes
Notes
Quinlan 2004
Methods Prospective, randomised, placebo-controlled study.
Participants
Patients meeting the American European Consensus criteria for acute lung injury Interventions 1) Intervention (n=10) received albumin (25g of a 25% solution) every 8 hrs for a total of nine doses.
2) Control (n=10) received normal saline administered in identical fashion and volume Outcomes Deaths noted.
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment (selection bias) Unclear risk "Patients were randomized to receive 25g of human albumin every 8 hrs or a placebo (normal saline, administered in a doubleblind fashion and targeted to normalization of serum total protein." p. 755 -756
Rackow 1983
Methods Randomised controlled trial. Method of allocation concealment not described Participants Participants were above 18 years of age, and had any one of the following pre-determined indicators of shock: systolic blood pressure of 90mmHg or less, a cardiac index of less than 2.2L./min.m2, a serum arterial lactate greater than 18mg/dl and WP less than 15mmHg
Interventions 1) Intervention group ( n= 9) received 5% albumin.
2) Control group (n=8) received 0.9% NaCl. Allocated fluid was given as needed until the end of resuscitation Outcomes Deaths reported.
Notes
Rubin 1997
Methods Patients were randomised using "a closed envelope system in the pharmacy" 
Notes
Risk of bias
Bias Authors' judgement Support for judgement
SAFE 2004
Methods Central randomisation accessed on the Internet through a secure website with use of a minimisation algorithm. Blinding was assured through the use of specially designed masking cartons and specially designed and manufactured administration sets. The authors report that the effectiveness of the blinding was confirmed in a formal study before the trial was initiated Participants Patients 18 years of age or older admitted to ICU who the treating clinician judged to require fluid administration to maintain or increase intravascular volume, with this decision supported by the fulfilment of at least one objective criterion. Patients admitted after cardiac surgery, after liver transplantation, or for the treatment of burns were excluded Interventions 1) 4% Albumin or 2) Normal saline The allocated study treatment was used for all fluid resuscitation in the ICU until death or discharge or until 28 days after randomisation. The treating clinicians determined the amount and rate of fluid administration according to each patient's clinical status and response to treatment Outcomes Deaths reported.
Notes 28 day mortality.
Risk of bias
Bias Authors' judgement Support for judgement
Allocation concealment (selection bias) Low risk "Randomization was carried out centrally with the use of a minimization algorithm and the service was accessed on the Internet through a secure Web site." p. 2248
Shah 1977
Methods Randomised controlled trial, allocation by sealed envelope.
Participants
Patients with severe, multiple trauma and a systolic blood pressure of less than 90mmHg. All patients were adults and both sexes were included 
Notes
Length of follow-up not stated. 
Risk of bias
Outcomes
Unpublished data on deaths were provided by the trialist.
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Wojtysiak 1992
Methods Randomised controlled trial. 
Notes
Risk of bias
Bias Authors' judgement Support for judgement
Zetterstrom 1981a
Methods
The patients were randomly divided into two groups. The method of allocation concealment is not described. Author was contacted and confirmed the use of sealed opaque envelopes Participants Adult patients undergoing elective major abdominal surgery.
Interventions 1) Intervention group (n=15) 2) Control group (n=15) A similar schedule of fluid therapy and blood replacement was followed in the intervention and control groups. However, the albumin group received a 20% solution of human albumin intravenously according to the following scheme: At the end of the operation: 100ml. Postoperatively on the day of the operation: 200-300 ml. First day after the operation: 200 ml. Following 3 days 100 ml each day.
Outcomes
Notes
Length of follow-up unspecified. Grundmann 1985 This was a randomised controlled trial of 220 patients, 106 were given albumin when their colloid osmotic pressure (COP) fell below 24 cm water and 114 were given albumin when their COP fell below 29 cm water. Patients were not randomised to albumin or no albumin, nor were they randomised to supplemental albumin versus normal amounts of albumin, rather, this was a trial of different criteria for albumin supplementation. It is unlikely therefore that the two arms of the trial were comparable and hence the trial is excluded
Risk of bias
Grundmann 1986 This was a randomised controlled trial to examine whether postoperative human albumin supply is justified in intensive care patients in the case that the colloid osmotic pressure decreases below 26 centimetres of water. The therapy group received human albumin only if the colloid osmotic pressure dropped below 26 cm water. The control group also received albumin but only for resuscitation of cardiac output and central venous pressure. The trial was excluded because both intervention and control groups received albumin
Hauser 1980
Cross-over trial.
Lagonidis 1995
Intervention was pre-loading for coronary artery bypass surgery
Lennihan 2000
Participants had suffered subarachnoid hemorrhage and therefore did not meet the inclusion criteria Magder 1999 Participants were stable patients following cardiopulmonary bypass surgery and therefore did not meet the inclusion criteria
Maitland 2005a
Trial was subset of SAFE 2004 trial, thus offering no new data.
Martin 1999
Intervention involved comparison of albumin with furosemide verus placebo therefore did not meet the inclusion criteria
Metildi 1984
Participants were admissions to an intensive care and a trauma unit with adult respiratory distress syndrome and established pulmonary failure. Included both trauma and non-trauma patients and therefore did not meet the inclusion criteria for the review Steinberg 1989 Cross-over trial.
Tomita 1994
Randomised controlled trial of normal versus high oncotic pressure following head injury. Patients were not randomised to albumin or no albumin. Albumin and furosemide were used together to achieve high oncotic pressure Heterogeneity: Chi 2 = 26.66, df = 31 (P = 0.69); I 2 =0.0%
D A T A A N D A N A L Y S E S
Test for overall effect: Z = 0.93 (P = 0.35)
Test for subgroup differences: Chi 2 = 6.96, df = 2 (P = 0.03), I 2 =71% 0.02 0.1 1 10 50
Favours treatment Favours control
A P P E N D I C E S Appendix 1. Search strategy
PubMed [www.ncbi.nlm.nih.gov/sites/entrez/] (searched 10 June 2011 limit: last 60 days) Cochrane Injuries Group Specialised Register (searched 31 May 2011) 1.fluid* and (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*) 2.rehydrate* and (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*) 3.volum* and (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*) 4.1 or 2 or 3 5.Albumin* 6.4 and 5
Cochrane Central Register of Controlled Trials 2011, Issue 2 (The Cochrane Library) #1MeSH descriptor Fluid Therapy explode all trees #2fluid* #3((volume or rehydrat*) near3 (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*)) #4(#1 OR #2 OR #3) #5MeSH descriptor Albumins explode all trees #6MeSH descriptor Serum Albumin explode all trees #7albumin* #8(#5 OR #6 OR #7) #9(#4 AND #8) #10(#9), from 2008 to 2011 MEDLINE (Ovid) 1948 to Week 3 May 2011 1.exp Fluid Therapy/ 2.fluid*.ti,ab. 3.((volume or rehydrat*) adj3 (solution* or replac* or therap* or substitut* or restorat* or resuscitat* or rehydrat*)).ti,ab. 4.1 or 2 or 3 5.exp Albumins/
